What is the next step for a patient with elevated Hematocrit (Hct) due to Xyosted (Testosterone)

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Elevated Hematocrit from Xyosted (Testosterone)

When hematocrit exceeds 54% on Xyosted, you must intervene immediately by either reducing the testosterone dose, temporarily discontinuing therapy, or performing therapeutic phlebotomy. 1, 2

Immediate Assessment and Intervention Thresholds

Critical Hematocrit Values

  • Hct >54%: Mandatory intervention required 1, 2, 3
  • Hct 50-54%: Close monitoring with consideration for intervention 1
  • Baseline Hct >50%: Withhold testosterone until etiology is investigated 1

First-Line Interventions (Choose One or Combine)

Option 1: Therapeutic Phlebotomy

  • Recommended as first-line intervention to remove excess red blood cells and reduce cardiovascular/thromboembolic risk 2
  • Important caveat: Evidence supporting phlebotomy efficacy is actually lacking, and it may paradoxically increase thrombotic risk by lowering tissue oxygen and depleting iron stores 4
  • Blood donation alone is often insufficient to maintain Hct <54% in repeat donors 5

Option 2: Dose Reduction

  • Reduce Xyosted dosage to decrease erythropoiesis stimulation 1, 2, 3
  • Injectable testosterone (like Xyosted) carries the highest risk of erythrocytosis (43.8%) compared to transdermal preparations (15.4%) 2

Option 3: Temporary Discontinuation

  • Withhold testosterone therapy until hematocrit normalizes 1, 2, 3
  • Resume at lower dose once Hct returns to acceptable range 1

Modifiable Risk Factor Management

Address these factors to reduce erythrocytosis risk:

  • Tobacco cessation: Smoking increases odds of erythrocytosis 2.2-fold 6
  • Weight loss if BMI elevated: High BMI increases odds 3.7-fold 6
  • Consider switching formulations: Change from injectable (Xyosted) to transdermal testosterone gel, which has significantly lower erythrocytosis rates 2, 6

Monitoring Schedule Going Forward

After intervention:

  • Recheck hemoglobin/hematocrit at 1-2 months after any dose adjustment 1, 2
  • Continue monitoring every 3-6 months during first year 1, 2
  • Annual monitoring thereafter if stable 1, 2

Additional Screening to Perform Now

Rule out other causes of elevated hematocrit:

  • Assess for chronic obstructive pulmonary disease or other pulmonary conditions (OR 2.5 for erythrocytosis) 6
  • Evaluate for sleep apnea 1
  • Consider polycythemia vera if hematocrit remains elevated off testosterone 6

Key Clinical Pitfalls

  • Do not assume blood donation alone will control hematocrit: 44% of repeat donors on testosterone maintained persistently elevated hemoglobin despite regular donation 5
  • Injectable testosterone is highest risk: Xyosted (testosterone enanthate auto-injector) carries substantially higher erythrocytosis risk than gels 2
  • Hematocrit rises most in first year: The largest increase occurs in year one (0.39 to 0.45 L/L), but risk continues accumulating over time (10% at 1 year, 38% at 10 years) 6
  • The 54% threshold is somewhat arbitrary: Limited evidence directly links this specific cutoff to adverse cardiovascular events, though it remains the guideline-recommended intervention point 1, 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Guidelines for Therapeutic Phlebotomy with Testosterone Replacement Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Testosterone therapy and secondary erythrocytosis.

International journal of impotence research, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.